secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2026-05-27T21:13:33+00:00
Accession:  0001935979-26-000048
Event type: other_material
Sentiment:  positive
Materiality: 0.95
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Biohaven reports positive clinical data for opakalim in epilepsy and BHV-1300/BHV-1400 in autoimmune diseases at R&D Day
--------------------------------------------------------------------------------

- Opakalim 75 mg prolonged median time to second seizure to 141 days vs 47 days for placebo in idiopathic generalized epilepsy trial.
- 54% of focal epilepsy patients on opakalim achieved ≥50% seizure reduction over six months in open-label extension.
- BHV-1300 reduced pathogenic TSHR-IgG1 >80% by week 12 and normalized thyroid hormones within weeks in Graves' disease patients.
- BHV-1400 reduced Gd-IgA1 >60% within hours and 70% within one month in IgA nephropathy, with early eGFR and UPCR improvements.
- Both degrader programs showed well-tolerated safety profiles with no serious adverse events; pivotal Phase 3 trials expected to initiate mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597926000048/0001935979-26-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597926000048/bhvn-20260526.htm
  HTML page:      https://secwatch.observer/filing/0001935979-26-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer